Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Special drug use surveillance of Takecab (vonoprazan) tablets for prevention of recurrence of gastric/duodenal ulcer in patients receiving low-dose aspirin
jRCT1080223380Completed
- Sponsor
- Takeda
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vonoprazan in gastric ulcer, duodenal ulcer and Peptic ulcer disease (PUD), sponsored by Takeda. Primary endpoints: Safety of long-term vonoprazan use and Effectiveness in preventing ulcer recurrence. Started Nov 2016; status: completed.
02
Drugs
vonoprazan
03
Conditions
gastric ulcerduodenal ulcerPeptic ulcer disease (PUD)
Beyond the preview
Go deeper on jRCT1080223380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223380.